Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Breast Cancer Clinical Trials in Tennessee | 983 Studies

Clinical Trials Breast CancerTennessee

Breast Cancer Clinical Trials in Tennessee

Find 983 clinical trials for breast cancer near Tennessee. Connect with research centers in your area.

All Breast Cancer trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 261-280 of 983 trials

RecruitingAssessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsThis is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are…NCT06418204·Fairbanks, Alaska and 466 others

Breast Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingStudy of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesThis study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK)…NCT05783622·Duarte, California and 17 others

CompletedTAC Versus TC for Adjuvant Breast CancerThe purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.NCT00493870·Birmingham, Alabama and 94 others

RecruitingThe PREDICT Registry:This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions.NCT03448926·Scottsdale, Arizona and 29 others

CompletedA First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast CancerThis is a phase I, open-label study of D-0502 single agent and D-0502 in combination with standard dose of palbociclib to assess the safety and tolerability, identify an MTD…NCT03471663·Fresno, California and 14 others

RecruitingA Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast CancerThis is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor…NCT05187832·Nashville, Tennessee

RecruitingEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsThe objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and…NCT05983432·Beverly Hills, California and 36 others

RecruitingA Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsThis is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1)…NCT05941507·Los Angeles, California and 7 others

TerminatedChronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell TransplantRATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to…NCT00957736·Nashville, Tennessee and 2 others

Active not recruitingA Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with…NCT04546009·Fountain Valley, California and 254 others

Active not recruitingStudy of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast CancerThis clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or…NCT05654532·Denver, Colorado and 8 others

CompletedStudy of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerA randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery)…NCT04109066·Mobile, Alabama and 239 others

CompletedFulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast CancerThe purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in…NCT00093002·Little Rock, Arkansas and 30 others

CompletedNeoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast CancerThis trial will examine the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer.NCT00887575·Fort Lauderdale, Florida and 13 others

RecruitingStudy of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.NCT05898399·Grand Rapids, Michigan and 17 others

CompletedDocetaxel in Treating Patients With Solid TumorsRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00003565·Anniston, Alabama and 73 others

RecruitingA Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerPUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with…NCT06369285·Birmingham, Alabama and 52 others

Active not recruitingA Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence.NCT04622319·Anaheim, California and 481 others

TerminatedSafety Study of MGD009 in B7-H3-expressing TumorsThe purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors.NCT02628535·Los Angeles, California and 19 others

CompletedPazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)Pazopanib will be given with TAXOL in one part, in another part pazopanib will be given with TAXOL and PARAPLATIN, and in a third part pazopanib will be given with TAXOL and…NCT00388076·New Brunswick, New Jersey and 2 others

PreviousPage 14 of 50Next

Other Conditions in Tennessee

Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma